Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMG-7289 in Essential Thrombocythemia
NCT04081220Phase 2Active, not recruiting
- Sponsor
- UT Health San Antonio
- Start
- Apr 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat in essential thrombocythemia (ET), sponsored by UT Health San Antonio. Primary endpoint: Complete Hematologic Remission at 24 weeks. Started Apr 2020; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04081220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081220.